retatrutide peptide clinical trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Vial of unapproved peptide retatrutide

As of early 2025, well over 30 new GLP-1 drugs are in development

From other trials, there are health benefits in a reduction of weight-related comorbidities when individuals lose 5-10% of body weight, so it is very likely their health improved

These medicines, including liraglutide, albiglutide, dulaglutide, and semaglutide, were synthesised using strategic changes of the human GLP-1 molecule to diminish its vulnerability to DPP-4 breakdown

did not observe significant differences in amputation risk between GLP-1 receptor agonists, SGLT-2 inhibitors, and other diabetes medications in a large retrospective cohort study of 1,222,436 patients with type 2 diabetes

A small adjustment in timing can make a big difference in your comfort level

Oral options are emerging quickly, including oral semaglutide formulations and orforglipron, marketed as Foundayo